JPMorgan ups Amplifon to 'overweight', attractive entry point ahead of re-rating

Demant A/S

27/07/2026 13:01

** JPMorgan ups Italy's Amplifon AMPF.MI to "overweight" from "neutral" with an unchanged PT of €16.70 ($19.03), seeing an attractive entry point in the Hearing Aid company 
** Its stock is up by over 3.5%, the best performer on Italy's blue-chip index .FTMIB  
** After a slower 2025, there's scope for the Hearing Aid market "to accelerate in 2026 to levels above that assumed in all the companies' guidance", the broker said in reference also to peers like Demant DEMANT.CO and Sonova SOON.S  
** With Amplifon's shares "significantly de-rated," - down 20% YTD up to the previous session's close - J.P.Morgan sees recovery potential and an upside over 50% for the group following the GN Hearing GN.CO acquisition and subsequent synergies 
** Out of 17 analysts that cover Amplifon, six rate the stock "buy," ​ten rate it "hold" and one rates the stock "sell" - LSEG data
  


($1 = 0.8773 euros)

 (Reporting by Fabrizio La Rocca)
 ((Fabrizio.larocca@thomsonreuters.com))